Eli Lilly Announced Sunday At ESMO, Olomorasib Plus Chemoimmunotherapy Data Showing 62% Overall Response Rate, 14.5-Month Median Response Duration In First-Line KRAS G12C NSCLC

Loading news article.

Eli Lilly Announced Sunday At ESMO, Olomorasib Plus Chemoimmunotherapy Data Showing 62% Overall Response Rate, 14.5-Month Median Response Duration In First-Line KRAS G12C NSCLC | WAPE

Eli Lilly Announced Sunday At ESMO, Olomorasib Plus Chemoimmunotherapy Data Showing 62% Overall Response Rate, 14.5-Month Median Response Duration In First-Line KRAS G12C NSCLC

Article summary

Related companies

Comments —